Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital has reiterated its Buy rating for EyePoint Pharmaceuticals, maintaining a price target of $28.
October 29, 2024 | 10:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital has reiterated its Buy rating for EyePoint Pharmaceuticals, maintaining a price target of $28.
The reaffirmation of a Buy rating and a specific price target by Chardan Capital is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100